Form 8-K - Current report:
SEC Accession No. 0000950170-23-005714
Filing Date
2023-03-02
Accepted
2023-03-02 07:35:24
Documents
15
Period of Report
2023-03-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dyn-20230302.htm   iXBRL 8-K 70275
2 EX-99.1 dyn-ex99_1.htm EX-99 150917
3 GRAPHIC img259164492_0.jpg GRAPHIC 34220
4 GRAPHIC img259164492_1.jpg GRAPHIC 631
  Complete submission text file 0000950170-23-005714.txt   403716

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dyn-20230302_lab.xml EX-101.LAB 17762
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dyn-20230302.xsd EX-101.SCH 2468
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dyn-20230302_pre.xml EX-101.PRE 11112
9 EXTRACTED XBRL INSTANCE DOCUMENT dyn-20230302_htm.xml XML 4697
Mailing Address 1560 TRAPELO ROAD WALTHAM MA 02451
Business Address 1560 TRAPELO ROAD WALTHAM MA 02451 (781) 786-8230
Dyne Therapeutics, Inc. (Filer) CIK: 0001818794 (see all company filings)

EIN.: 364883909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39509 | Film No.: 23696434
SIC: 2834 Pharmaceutical Preparations